Following dynamite data that earned a standing ovation at the American Society of Clinical Oncology in June, Revolution ...

Less than a month after initiating a drug recall after cardboard was fou | Baxter has initiated a recall of two products ...

Fresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody ...

Teva is increasingly highlighting its innovative drug bona fides these days, seeking to style itself as both a novel ...

As the leadership vacuum at the top of the FDA looks poised to close with President Donald Trump’s nominee pick for a ...

McKesson Corporation is expanding its drug development and commercialization capacity to the tune of $2.25 billion. | The ...

Jazz Pharmaceuticals’ bispecific antibody Ziihera has gained an FDA approval for first-line HER2-positive stomach cancer, ...

Bausch + Lomb has come up short in a phase 2 trial, testing its combination of dry eye disease drugs Xiidra and Miebo. | ...

Just 16 months after Johnson & Johnson scored its initial FDA app | Sixteen months after Johnson & Johnson scored its initial ...

On Monday, the U.S. Court of Appeals for the Third Circuit in Washington, D.C., ruled against Merck & Co., rejecting its ...

With its ascent seemingly unstoppable in the last few years, automated cell therapy manufacturer Cellares is facing some ...

HHS Secretary Robert F. Kennedy Jr. has joined President Donald Trump in a renewed effort to challenge how the United States ...